Home OTC Markets Litigation Blog Press Subscribe Racing Contact
   Consultants to public companies, brokers, attorneys, regulators and OTC Markets Group, Inc.
Why I Own Shares of Vivos, Inc. (RDGL)
Initially Posted: July 17, 2018 1:10 p.m. PDT   

As most of my followers know, I have earned a reputation for calling out penny stock scams. In spite of many detractors, usually consisting of those parties participating in such schemes, my tactics have been successful in ending many programs designed to defraud the public, albeit not before some people get hurt. Corix Bioscience (CXBS) comes to mind. Often, my work has lead to the incarceration of the perpetrators of such schemes, including and especially attorneys.

The OTC Markets (not to be confused with OTC Markets Group) is and continues to be the wild west of the stock market. When people ask me which tickers I would endorse, my answer almost invariably is, "Stay away from penny stocks". This is because I truly believe that almost every single ticker trading on the pink sheets and OTCQB---I would agree that a select few are real companies--is a scam, subject to a pump and dump scheme of some sort.

Although I have bought certain OTC tickers in the past, it has almost always been with the intent to gain rights as a shareholder so that I can subpoena the business records of the company1. Before today, I have never bought into an OTC ticker as an investment.

So here I am, accepting several past challenges to write something positive for a change. That is not an endeavor I find easy to accomplish in the OTC market.

This afternoon, I started accumulating shares of Vivos, Inc., ticker symbol RDGL.

I came across this company purely by accident. On most trading days, I scan the list of most active tickers to see what might be the newest pump and dump scheme. Today's action in RDGL, which is certainly a mystery to me, considering that the company has not issued a press release since May 31, drew my attention to the company2. I fully expected to find some sort of promotion ongoing, but have not thus far. That does not mean that there isn't one, although I hope not.

I am not going to go into a complete analysis of the financial position of the company, except to say that it has no money and no revenues. This is not unusual in a drug company that is researching its first treatment. The company has debt of about $5 million, but it is probably not insurmountable, especially considering the progress they are reporting with their cancer treatments. Most of the debt is in convertible notes which could eventually lead to dilution, but I have a gut feeling about this one. I think that the company may be able to get into research partnerships as they accomplish additional successful treatments, and that could alleviate those debts. Nonetheless, I find it encouraging that management does not appear to me to be taking a salary or consulting fees or is engaging in any other form of siphoning funds from the company. To me, this means that management is in it for the end game and not to steal from the shareholders. Hopefully, I am correct.

As I said, I am encouraged by news of progress, but I am accepting it at face value, not something I generally do. The company's most recent press release announced that it had "successfully treated canine soft tissue sarcoma with its proprietary IsoPet™ (RadioGel™), a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor." This is seemingly enormous news and together with previous announcements of success, enticed me enough to dip a cautious toe in the water.

~ George

P.S. Any claims of short positions (and squeezes) that will precipitate buying of Vivos stock (or any other penny stock for that matter) is utter nonsense, as is any claim of market maker manipulation.  Stocks go up when there are more buyers than sellers and go downs when there are more sellers than buyers.  That's the stock market.

About Vivos Inc. (as reported by the Company)
Currently, the Company has developed an Yttrium-90 based brachytherapy device, for the treatment of tumors in animals and humans. Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area. The product delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.
IsoPetTM for treating animals uses the same technology as RadioGelTM for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.
IsoPetTM is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. This hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial space after injection to keep the radiation source safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

IsoPetTM also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to the family.
The IsoPetTM Solutions division of RDGL is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. The testing on feline sarcoma at the Washington State University is completed and the testing on canine soft tissue sarcomas at University of Missouri will begin in the near future.

The Company recently obtained clarification from the FDA Center for Veterinary Medicine that IsoPet is classified as a device for skin cancer therapy in cats and dogs. The FDA also reviewed and approved the product labeling. FDA does not require pre-market approval for veterinary devices so no additional approval is required for treating skin cancer, which is the largest market sector. RDGL is positioning itself so that after this demonstration phase, The Company can begin to generate revenues through the sale of IsoPetTM to University animal hospitals and private veterinary clinic consortiums.
The Company is also engaging the FDA for permission to use RadioGelTM for the treatment of advanced basal and squamous cell skin cancers in humans.

Disclaimer: As of the writing of this blog post, I own one million shares of Vivos, Inc. (RDGL). I reserve the right to buy or sell shares without further notice. I have not been compensated for this post in any way and the company was not aware that I was writing this blog post. I have reached out to the company to offer my services in their endeavor. This investment carries a very high risk and I am prepared to lose all of my money, provided that the company is acting in a truthful manner with the goal of benefiting the shareholders.

1 In the case of Corix Bioscience, I received shares as compensation for a judgment I held against the previous owner of the shares.

2 On July 17, 2018 at 10:10 a.m. PDT, I tweeted about my purchase in Vivos stock.  An almost immediate spike in volume and share price occurred which may or may not have been a reaction to that tweet.